2025 Kicks off With Several Big Biopharma Deals
With the JP Morgan 43rd Annual Healthcare Conference underway in San Francisco this week, the Biotechnology and Pharmaceutical (Biopharma) sectors are seeing a flurry of activity. Many large-scale acquisitions and licensing agreements are being announced, setting the tone for an eventful year ahead in the industry. So far this year, 14 Biopharma deals have been announced (as of January 15, 2025). Deal values have reached $15.7 billion, a significant increase from the same period in recent years. During the same time frame in 2024, there were also 14 Biopharma deals announced, but their combined value was just $4 billion. Looking back to 2023, the first two weeks saw 17 Biopharma deals, but... Read More »
Cube Biotech Acquires IBA Lifesciences
Cube Biotech, a portfolio company of private equity firm Archimed, announced on January 14 that it entered into an agreement to acquire IBA Lifesciences. IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. It is based in Goettingen, Germany and was founded in 1996. Backed by Archimed since 2021, Cube Biotech is a biotechnology company based in Monheim, Germany. It is a provider of solutions for protein purification, stabilization and structural studies. The combination of the two companies will leverage their complementary strengths to deliver solutions in protein... Read More »
Johnson & Johnson Buys Intra-Cellular Therapies For $14.6 Billion
Johnson & Johnson (J&J) announced on January 13 that it will acquire all outstanding shares of Intra-Cellular Therapies for $132.00 per share in cash for a total equity value of approximately $14.6 billion. Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders. According to its most recent annual report, Intra-Cellular Therapies had revenues of $462 million during fiscal year (FY) 2023, and EBITDA was reported as a loss of nearly $158.9 million during FY 2023. Intra-Cellular has developed CAPLYTA® (lumateperone), a once-daily oral therapy approved to treat adults with... Read More »
Novartis Acquires Kate Therapeutics for up to $1.1 Billion
Novartis announced on November 21 that it has acquired Kate Therapeutics to further enhance and strengthen its ongoing efforts to advance gene therapies for patients. Under the terms of the agreement, Kate Therapeutics’ shareholders are entitled to receive up to $1.1 billion, in a combination of upfront cash and potential milestone payments. The exact amount of the upfront payment was not disclosed. San Diego-based Kate Therapeutics is a patient-focused biotechnology company developing adeno-associated virus-based gene therapies to treat genetically defined muscle and heart diseases. Kate is focused on preclinical programs aimed at Duchenne muscular dystrophy,... Read More »
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
On October 28, AbbVie and Aliada Therapeutics announced a definitive agreement under which AbbVie will acquire Aliada. Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. Aliada Therapeutics is a biotechnology company focused on addressing delivery challenges in central nervous system (CNS) drug development. Aliada uses a novel blood-brain barrier-crossing technology to address challenging CNS diseases. Aliada’s lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
